ProfoundBio Cleared to Start US Trials of ADC for Solid Tumor Cancers
publication date: Aug 4, 2022
ProfoundBio, a Suzhou-Seattle oncology biopharma, was approved to start US trials of an antibody drug candidate in patients with advanced cancers. PRO1184 consists of a folate receptor alpha (FRa) directed antibody conjugated to an exatecan payload with a novel hydrophilic linker. The Phase 1 trial will evaluate the safety, activity and pharmacokinetics of PRO1184 in patients with ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma. ProfoundBio develops novel antibody therapeutics aimed at solid tumor cancers. In 2021, Profound was formed with $58 million in capital from China investors and leadership from SeaGen veterans. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.